

Leap Therapeutics Inc (LPTX) - Financial and Strategic SWOT Analysis Review

<https://marketpublishers.com/r/LAE7F9C3C39EN.html>

Date: August 2021

Pages: 43

Price: US\$ 125.00 (Single User License)

ID: LAE7F9C3C39EN

Abstracts

Leap Therapeutics Inc (LPTX)

Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Leap Therapeutics Inc (Leap Therapeutics) is a clinical-stage biopharmaceutical company that develops novel therapeutics to treat patients with cancer. The company's pipeline products include DKN-01 and TRX518. DKN-1 is a monoclonal antibody that targets the Dickkopf-1 (DKK-1) protein, intended for the treatment of gastroesophageal cancer, hepatobiliary cancer, prostate cancer and gynecologic cancer. TRX518 is a humanized anti-GITR (glucocorticoid-induced tumor necrosis factor receptor) monoclonal antibody that enhances the immune system's anti-tumor response and is intended for the treatment of solid tumors. Leap Therapeutics is headquartered in Cambridge, Massachusetts, the US.

Leap Therapeutics Inc Key Recent Developments

May 14, 2021: Leap Therapeutics Reports First Quarter 2021 Financial Results

Feb 22, 2021: Leap Therapeutics to Present at Upcoming Virtual Investor Conferences

Aug 24, 2020: Leap Therapeutics expands leadership team with addition of two industry veterans

Aug 13, 2020: Leap Therapeutics reports second quarter 2020 financial results

May 14,2020: Leap Therapeutics reports first quarter 2020 financial results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

- Leap Therapeutics Inc - Key Facts
- Leap Therapeutics Inc - Key Employees
- Leap Therapeutics Inc - Key Employee Biographies
- Leap Therapeutics Inc - Major Products and Services
- Leap Therapeutics Inc - History
- Leap Therapeutics Inc - Company Statement
- Leap Therapeutics Inc - Locations And Subsidiaries
 - Head Office
 - Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

- Company Overview
- Leap Therapeutics Inc - Business Description
 - Business Segment: License Revenue
 - Performance
 - R&D Overview
- Leap Therapeutics Inc - Corporate Strategy
- Leap Therapeutics Inc - SWOT Analysis
 - SWOT Analysis - Overview
 - Leap Therapeutics Inc - Strengths
 - Leap Therapeutics Inc - Weaknesses
 - Leap Therapeutics Inc - Opportunities
 - Leap Therapeutics Inc - Threats
 - Leap Therapeutics Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

- Financial Ratios - Capital Market Ratios
- Financial Ratios - Annual Ratios
- Performance Chart
- Financial Performance
- Financial Ratios - Interim Ratios
- Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Leap Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Leap Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021

Leap Therapeutics Inc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

May 14, 2021: Leap Therapeutics Reports First Quarter 2021 Financial Results

Feb 22, 2021: Leap Therapeutics to Present at Upcoming Virtual Investor Conferences

Aug 24, 2020: Leap Therapeutics expands leadership team with addition of two industry veterans

Aug 13, 2020: Leap Therapeutics reports second quarter 2020 financial results

May 14, 2020: Leap Therapeutics reports first quarter 2020 financial results

Mar 16, 2020: Leap Therapeutics reports fourth quarter and full year 2019 financial results

Jan 06, 2020: BeiGene obtains certain rights for Leap Therapeutics’ cancer drug

SECTION 6 – APPENDIX

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Leap Therapeutics Inc, Key Facts
Leap Therapeutics Inc, Key Employees
Leap Therapeutics Inc, Key Employee Biographies
Leap Therapeutics Inc, Major Products and Services
Leap Therapeutics Inc, History
Leap Therapeutics Inc, Subsidiaries
Leap Therapeutics Inc, Key Competitors
Leap Therapeutics Inc, Ratios based on current share price
Leap Therapeutics Inc, Annual Ratios
Leap Therapeutics Inc, Annual Ratios (Cont...1)
Leap Therapeutics Inc, Interim Ratios
Leap Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Leap Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Leap Therapeutics Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Leap Therapeutics Inc, Performance Chart (2016 - 2020)

Leap Therapeutics Inc, Ratio Charts

Leap Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD
2021

Leap Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD
2021

I would like to order

Product name: Leap Therapeutics Inc (LPTX) - Financial and Strategic SWOT Analysis Review

Product link: <https://marketpublishers.com/r/LAE7F9C3C39EN.html>

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/LAE7F9C3C39EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970